Last reviewed · How we verify
Tabirafusp tedromer
Tabirafusp tedromer is a fusion protein that targets the interleukin-4 receptor alpha subunit.
Tabirafusp tedromer is a fusion protein that targets the interleukin-4 receptor alpha subunit. Used for Allergic asthma.
At a glance
| Generic name | Tabirafusp tedromer |
|---|---|
| Also known as | KSI-501 |
| Sponsor | Kodiak Sciences Inc |
| Drug class | IL-4 receptor alpha antagonist |
| Target | IL-4Rα |
| Modality | Small molecule |
| Therapeutic area | Allergy |
| Phase | Phase 3 |
Mechanism of action
It works by binding to the interleukin-4 receptor alpha subunit, thereby inhibiting the activity of interleukin-4, a cytokine involved in the pathogenesis of allergic diseases.
Approved indications
- Allergic asthma
Common side effects
- Injection site reactions
- Headache
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tabirafusp tedromer CI brief — competitive landscape report
- Tabirafusp tedromer updates RSS · CI watch RSS
- Kodiak Sciences Inc portfolio CI